We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 53.00 | 2.92% | 1,866.00 | 1,864.00 | 1,866.00 | 1,866.00 | 1,750.00 | 1,750.00 | 165,417 | 12:45:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.23 | 4.08B |
From Apr 2019 to Apr 2024
LONDON--Hikma Pharmaceuticals PLC (HIK.LN) said Monday it has signed an exclusive licensing and distribution agreement with Finnish pharmaceutical company Orion Corporation, for Orion's new Easyhaler combination product, a dry powder inhaler, for the treatment of asthma and chronic obstructive pulmonary disease.
The agreement gives Hikma the exclusive rights to register, distribute, market and sell the product in all of its Middle East and North Africa or MENA markets.
Hikma shares at 0925 GMT up 14 pence, or 0.7%, at GBP19.51, valuing the company at GBP4.68 billion.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
February 13, 2017 04:43 ET (09:43 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
